Medicinova
$1.42
15
+$0.05+3.65% Wednesday 20:00
Statistics
Day High
1.44
Day Low
1.38
52W High
1.96
52W Low
1.13
Volume
56,657
Avg. Volume
74,913
Mkt Cap
69.65M
P/E Ratio
-
Dividend Yield
-
Dividend
-
Upcoming
Earnings
13MayExpected
Expected EPS
-0.08295
Actual EPS
N/A
Financials
-Profit Margin
Unprofitable0Revenue
-22.1MNet Income
Analyst Ratings
$8.33Average Price Target
The highest estimate is 10.00.
From 3 ratings within the last 6 months. This is not an investment recommendation.
From 3 ratings within the last 6 months. This is not an investment recommendation.
Buy 100%
Hold 0%
Sell 0%
People Also Follow
This list is based on the watchlists of people on Stock Events who follow MNOV. It's not an investment recommendation.
Competitors
This list is an analysis based on recent market events. It's not an investment recommendation.
Biogen
BIIB
Mkt Cap22.63B
Novartis
NVS
Mkt Cap237.61B
Gilead Sciences
GILD
Mkt Cap148.78B
Teva- Pharmaceutical Industries
TEVA
Mkt Cap23.49B
AMGEN
AMGN
Mkt Cap160.66B
Pfizer
PFE
Mkt Cap140.15B
Merck
MRK
Mkt Cap214.76B
Astrazeneca
AZN
Mkt Cap256.58B
Lilly(Eli) &
LLY
Mkt Cap772.28B
About
MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction. Its product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic diseases, including nonalcoholic steatohepatitis and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. The company has collaboration agreements with Kissei Pharmaceutical Co., Ltd.; Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals Ltd.; and Meiji Seika Kaisha Ltd. MediciNova, Inc. was incorporated in 2000 and is headquartered in La Jolla, California.
Show more...
CEO
Dr. Yuichi Iwaki M.D., Ph.D.
Employees
13
Country
US
ISIN
US58468P2065
Listings
0 Comments
Share your thoughts
FAQ
What is Medicinova stock price today?▼
The current price of MNOV is $1.42 USD — it has increased by +3.65% in the past 24 hours. Watch Medicinova stock price performance more closely on the chart.
What is Medicinova stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Medicinova stocks are traded under the ticker MNOV.
Is Medicinova stock price growing?▼
MNOV stock has risen by +0% compared to the previous week, the month change is a +0.71% rise, over the last year Medicinova has showed a +0.71% increase.
What is Medicinova market cap?▼
Today Medicinova has the market capitalization of 69.65M
When is the next Medicinova earnings date?▼
Medicinova is going to release the next earnings report on May 13, 2026.
What were Medicinova earnings last quarter?▼
MNOV earnings for the last quarter are -0.06 USD per share, whereas the estimation was -0.1 USD resulting in a +36.84% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Medicinova revenue for the last year?▼
Medicinova revenue for the last year amounts to 0 USD.
What is Medicinova net income for the last year?▼
MNOV net income for the last year is -22.1M USD.
How many employees does Medicinova have?▼
As of April 02, 2026, the company has 13 employees.
In which sector is Medicinova located?▼
Medicinova operates in the Health Care sector.
When did Medicinova complete a stock split?▼
The last stock split for Medicinova was on November 02, 2006 with a ratio of 1:10.
Where is Medicinova headquartered?▼
Medicinova is headquartered in La Jolla, US.